Valeant Pharma (VRX) Misses Q2 EPS by 8c, Reaffirms Guidance; Will Divest Ruconest Rights in N.A.

BTIG Remains Neutral on Valeant (VRX) Post-Q2; Sees Longer-than-Projected Path to Recovery

BTIG affirms Valeant Phama (NYSE: VRX) at Neutral following Q2 results from the company.

Analyst Timothy Chiang commented, While quarterly results were mixed, the Co. maintained its full year financial targets (which include revenues of $9.9 - $10.1B and EPS of $6.60 - $7.00). While... More

Valeant (VRX) PT Bumped to $22 at Piper Jaffray; Keeps Lowest Rating

Piper Jaffray analyst David Amsellem bumped his price target on Valeant Pharmaceuticals (NYSE: VRX) to $22.00 (from $19.00) but maintained an Underweight rating following results and reaffirmed guidance, which the analyst said may be overly optimistic.

Amsellem commented, "Valeant reported 2Q16 non-GAAP diluted EPS of $1.40 on revenue of $2.42B, lighter than Street... More

Valeant Pharma (VRX) Pushes to Session Highs

Valeant Pharma (NYSE: VRX) continues to push to the highs of the session following results and better-than-expected guidance. Shares are up 23.5% on volume that is running 5x the norm. Short covering is seen as a contributor to today's upside.

Valeant (VRX) Provides Plenty to Support Bullish Thesis - Guggenheim

Guggenheim analyst Louise Chen reiterated a Buy rating and $55 price target on Valeant Pharmaceuticals (NYSE: VRX) following a Q2 miss but reaffirmed '16 EPS guidance.

Chen notes, "VRX has noted since its 1Q16 call that it expects the business to recover in 2H16 as it moves past the issues with its derm business, and achieved its objective to report a 40%/60% earnings split between 1H16/2H16. Therefore, our investment thesis remains intact, and we continue to believe that VRX's growth... More

RBC Affirms Valeant (VRX) at 'Sector Perform'; Q2 Slightly Below Views, Walgreens Derm co-Pay Shows Improvement

RBC affirms Valeant (NYSE: VRX) Sector Perform with a price target of $31 following Q2 results on Tuesday.

Analyst Douglas Miehm offered the following quick commentary ahead of the company's conference call:

Total revenues in Q2/16 were $2.42B vs. our forecast of $2.47B, and consensus of $2.47B (FactSet,15 analysts, $2.30-2.66B range). Relative to our forecasts, the Derm, GI, and Neuro/Other segments came in below our expectations, and the Emerging... More